Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic Hamsters

Abstract

Elevated serum cholesterol is a major risk factor for coronary artery disease. Nutritional therapies such as probiotics have been suggested to manage elevated cholesterol. This study investigates the cholesterol and triglyceride lowering potential of a microencapsulated feruloyl esterase-producing Lactobacillus fermentum 11976 (LF11976) probiotic formulation. Male Bio F(1)B hamsters were assigned to two groups to receive either the microcapsule probiotic formulation (containing LF11976 cells at 12.51 log colony-forming units/mL) or placebo formulation (empty) microcapsules, twice daily, by oral gavage for 18 weeks. For the duration of the study, animals were fed a hypercholesterolemic diet. Serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and the atherogenic index were 21.36%, 31.43%, and 32.59% lower in the group gavaged with the microencapsulated probiotic formulation than in the placebo control group after 18 weeks (P < .05). Histology studies showed reduced progression of atherosclerotic lesions in animals treated with microencapsulated LF11976 as compared to control animals. Treatment with microencapsulated LF11976 formulation produces significant reductions in serum total cholesterol, LDL cholesterol, and serum triglyceride levels in diet-induced hypercholesterolemic hamsters. Findings suggest the potential of the oral microencapsulated probiotic cell formulation as a functional nutritional alternative for managing excessive serum cholesterol and triglyceride levels.

Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis

“…Promising research focuses on the microbial secretion and production of beneficial biologically active enzymes and proteins, including: ornithine decarboxylase for the treatment of autoimmune diseases and accelerated cell apoptosis [22], bile salt hydrolase for hypercholesterolemia [23;24], and bile transport and tolerance proteins for the efficient delivery of probiotics [25]. In recent studies, the products of another microbial protein, cinnamoyl esterase, have shown significant levels of antioxidant activity [10,26] and other effects, including stimulation of insulin secretion [17,27], prevention of oxidative stress [17], lipid peroxidation [28],cholesterol-lowering capabilities [9] and inhibition of diabetic nephropathy progression [29]. A product of hydrolysis activity of FAE,FA, is a well-characterised antioxidant [10].…”

“…This molecule is a potent antioxidant able to neutralize free radicals, such as Reactive Oxygen Species (ROS) [1] which have been implicated in DNA damage [2], cancer [3], accelerated cell aging [4], obesity [5] and type 2 diabetes mellitus (T2DM) [5,6]. A number of gastrointestinal tract (GIT) bacterial strains have been shown to produce feruloyl esterase (FAE) [7][8][9][10][11][12], an enzyme that hydrolyses and releases free FA from its bound state. Orally ingested FA-producing lactic acid bacteria should demonstrate an increased bioavailability of FA due to increased FAE activity in the intestine.…”

“…Microencapsulation in polymer membranes, such as alginate-polylysine-alginate (APA) has been shown to successfully protect live bacterial cells for oral delivery [8,11,14]. Specifically, the microencapsulation of FAE bacteria has demonstrated a higher viable cell count delivery through the GIT, allowing for a higher FA bioavailability [8,9,11].Previous research by our group has demonstrated that microencapsulated Lactobacillus fermentum ATCC 11976 (L.f. 11976) can be used as a probiotic formulation in the context of cholesterol management in a Bio F1B hypercholesterolemic Golden Syrian hamster model [9].…”

Effect of Orally Administered Microencapsulated FA-Producing L. fermentum on Markers of Metabolic Syndrome: An In Vivo Analysis

“…To investigate the therapeutic efficacy of the formulation, animals in the treatment group (n=12) received the microcapsule formulation containing 10 11 cfu of L.f. 11976 twice daily, a dose determined from previous work by our group [9]. The control group (n = 12) received empty microcapsules as treatment vehicle-control.…”

Physiological Characteristics and Anti-Obesity Effect of Lactobacillus plantarum K6 isolated from Kimchi

“…절, 혈중 콜레스테롤 저하, 과민성 대장증후군 같은 위장관 질환의 개선 효과, 암 예방, 면역체계 조절, 지질대사 개선 등의 연구 결과 가 보고되고 있다 (Bhathena et al, 2009;Lye et al, 2009;Rafter, 2004;Baken et al, 2006;Kim et al, 2014;Kang et al, 2013) …”